By the Top Tier Newswire AI Desk · October 6, 2026 at 12:03 AM ET · reviewed against 33 wire stories
VAXCYTE INC (PCVX) is up +31.01% in the latest session. Our newswire has captured 33 stories on PCVX across 15 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Vaxcyte Inc (PCVX) surged 31.01% to $73.82 in Monday trading, driven by the company’s announcement that its experimental pneumonia vaccine, VAX-31, met the primary endpoints of a late-stage study in adults aged 50 and older. The positive Phase 3 results positioned VAX-31 as a competitive alternative to existing vaccines from Pfizer and Merck. The stock also hit a fresh 52-week high during the session.
What Happened
Vaxcyte announced that its VAX-31 vaccine demonstrated noninferior immune responses compared to Pfizer’s Prevnar 20 and Merck’s Capvaxive in the OPUS-1 trial. This milestone marks a significant step toward potential regulatory approval and commercialization. The company also launched a $1 billion dual offering, including $500 million in common stock and $500 million in convertible senior notes, to fund further trials and scale-up efforts. While the stock initially surged on the trial success, it later faced downward pressure in after-hours trading following the announcement of the large capital raise. Analysts at BTIG reiterated their Buy rating on the stock, maintaining a $89 price target, while Needham raised its price target to $122.
What The Data Shows
The stock has gained 30.4% over the past eight sessions, rising from $55.99 to $73.03. On Monday alone, it closed at $73.82, surpassing its previous 52-week high of $65.00. The 52-week tape showed four fresh 52-week highs and 37 fresh 52-week lows on October 5. Unusual options activity included a notable $35,000 call premium print, with no put activity. Insiders have sold a total of $3.1 million in the last 90 days, while a congressional member, Rep. Gilbert Cisneros, Jr., disclosed a recent purchase of $1,001, $15,000 in the stock.
What To Watch
Investors should monitor Vaxcyte’s upcoming earnings, if any, and the reception of its dual offering. Coverage breadth remains elevated, with 33 stories from 15 sources in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AI sentiment, last 36h · averaged over 33 stories · 58/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
9h agoStocktwits NewsBULLISH 67Product/PR
NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test
Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.
11h agoInvesting.com MarketsBEARISH 34General
Why is Vaxcyte stock sliding in after-hours trading today?
Why is Vaxcyte stock sliding in after-hours trading today?
12h agoInvesting.com MarketsBEARISH 28General
Vaxcyte stock falls on $1B dual offering launch
Vaxcyte stock falls on $1B dual offering launch
12h agoThe FlyBEARISH 24General
Vaxcyte files to sell $500M of common stock, $500M of convertible senior notes
12h agoSeeking AlphaBEARISH 24General
Vaxcyte files separate $500M offerings for equity/pre-funded warrants and 2032 convertible notes
Vaxcyte (PCVX) launches $500M stock/warrant and $500M convertible notes offerings to fund VAX-31 trials, scale-up and U.S.
13h agoStockTitanBEARISH 28General
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded...
14h agoStocktwits NewsBULLISH 73Product/PR
PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case
In the OPUS-1 study, Vaxcyte’s VAX-31 matched or beat immune responses from Pfizer’s Prevnar 20 and Merck’s Capvaxive on most strains those vaccines cover.
BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →